ALOX15

Arachidonate 15-lipoxygenase
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols ALOX15 ; 12-LOX; 15-LOX-1; 15LOX-1
External IDs OMIM: 152392 MGI: 87997 HomoloGene: 44935 ChEMBL: 2903 GeneCards: ALOX15 Gene
EC number 1.13.11.31, 1.13.11.33
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 246 11687
Ensembl ENSG00000161905 ENSMUSG00000018924
UniProt P16050 P39654
RefSeq (mRNA) NM_001140 NM_009660
RefSeq (protein) NP_001131 NP_033790
Location (UCSC) Chr 17:
4.63 – 4.64 Mb		 Chr 11:
70.34 – 70.35 Mb
PubMed search

ALOX15 (also termed arachidonate 15-lipoxygenase, 15-lipoxygenase-1, 15-LO-1, 15-LOX-1) is a polyunsaturated fatty acid-metabolizing enzyme that in humans is encoded by the ALOX15 gene located on chromosome 17p13.3.[1] The 11 kilobase pair gene consists of 14 exons and 13 introns coding for a 75 kiloDalton protein composed of 662 amino acids. 15-LO is distinguished from another human 15-lipoxygenase enzyme, ALOX15B (15-lipoxygenase-2).[2] Orthologs of ALOX15, termed Alox15, are widely distributed in animal and plant species.

Nomenclature

Human ALOX15 was initially named arachidonate 15-lipoxygenase or 15-lipoxygenase but subsequent studies uncovered a second human enzyme with 15-lipoxygenase activity as well as various non-human mammalian that were closely related to and therefore orthologs of human ALOX15 but nonetheless possess 12-lipoxygenase rather than 15-lipoxygenase activity. Consequently, human ALOX15 is now referred to as arachidonate-15-lipoxygenase-1, 15-lipoxygenase-1, 15-LOX-1, 15-LO-1, human 12/15-lipoxygenase, leukocyte-type arachidonate 12-lipoxygenase, or arachidonate omega-6 lipoxygenase; the second discovered human 15-lipoxygenase, a product of the ALOX15B gene, is termed ALOX15B, arachidonate 15-lipoxygenase 2, 15-lipoxygenase-2, 15-LOX-2, 15-LO-2, arachidonate 15-lipoxygenase type II, arachidonate 15-lipoxygenase, second type, and arachidonate 15-lipoxygenase; and mouse, rat, and rabbit rodent orthologs of human ALOX15, which share 74-81% amino acid identity with the human enzyme, are commonly termed Alox15, 12/15-lipoxygenase (i.e. 12/15-LOX, and 12/15-LO).[1][2]

Human 15-LOX-1 (ALOX15) and 15-LOX-2 ALOX15B genes are located on chromosome 17; their product proteins have an amino acid sequence identity of only ~38%, differ in the polyunsaturated fatty acids that they prefer as substrates, and exhibit different product profiles when acting on the same substrates.[2][3]

Tissue distribution

Human ALOX15 protein is highly expressed in circulating blood eosinophils, bronchial airway epithelial cells, mammary epithelial cells, the Reed-Sternberg cells of Hodgkin's lymphoma, cornea epithelial cells, reticulocytes, and dendritic cells; it is less strongly expressed in alveolar macrophages, tissue mast cells, tissue fibroblasts, circulating blood neutrophils, vascular endothelial cells, joint Synovial membrane cells, seminal fluid, prostate epithelium cells, and mammary ductal epithelial cells.[4][5][6][7]

The distribution of Alox15 in sub-human primates and, in particular, rodents differs significantly from that of human ALOX15; this, along with there different principal product formation (e.g. 12-HETE rather than 15-HETE) has made the findings of Alox15 functions in rat, mouse, or rabbit models difficult to extrapolate to the function of ALOX15 in humans.[2]

Enzyme activities

Lipoxygenase acitivity

ALOX15 and Alox15 enzymes are non-heme iron-containing dioxygenases. They catalyze the dioxygenation (i.e. attachment of molecular oxygen, O
2, to polyunsaturated fatty acids (PUFA) that contain two carbon-carbon double bonds that are located between carbons 10 and 9 and 7 and 6 (as numbered counting backward from the last or omega [i.e. ω] carbon at the methyl end of the PUFA; these carbons are therefore also termed ω-10 and ω-9 and ω-7 and ω-6). In PUFAs that do not have a third carbon-carbon double bound between their ω-13 and ω-12 carbons, human ALOX15 forms ω-6 peroxy intermediates; in PUFAs that do have this third double bound, human ALOX15 makes the ω-6 peroxy intermediate but also small amounts of the ω-9 peroxy intermediate. Rodent Alox15 enzymes, in contrast, produce almost exclusively ω-9 peroxy intermediates. Concurrently, ALOX15 and Alox15 enzymes rearrange the carbon-carbon double bounds to bring them into a 1-2 and 3-4 diene configuration system and then reduce (see Redox sections on reduction) the peroxy residues to their hydroperoxy counterparts. The enzymes act with a high degree of Stereospecificity to form products of their naturally occurring substrates that have hydroperoxy residues in the S stereoisomer configuration.[8]

Lipohydroperoxidase activity

Human ALOX15 can also convert the peroxy PUFA intermediate to a cyclic ether with a three-atom ring, i.e. an epoxide intermediate that is attacked by a water molecule to form epoxy-hydrpoxy PUFA products.[2]

Leukotriene synthase activity

The PUFA epoxide intermediate of arachidonic acid may also be conjugated with glutathione to form Hepoxilins or analogs of hepoxilins.[2]

Substrates, substrate metabolites, and metabolite activities

Among their physiological substrates, human and rodent AlOX15 enzymes act on linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid when presented not only as free acids but also when incorporated as esters in phospholipids, glycerides, or Cholesteryl esters. The human enzyme is particularly active on linoleic acid, preferring it over arachidonic acid but is less active on PUFA that are esters within the cited lipids.[2]

Human ALOX15 metabolizes arachidonic acid, which has 4 double bonds all of which are in the cis (see Cis–trans isomerism or Z as opposed to the trans or E configuration between carbons 5-6, 8-9, 11-12, and 14-15. The reaction forms 15(S)-hydroperoxy-5Z, 8Z, 11Z, 13E-eicosatetraenoic acid (15(S)-HpETE) and 12(S)-hydroperoxy-5Z, 8Z, 10E, 15S-eicosatetraenoic acid (12(S)-HpETE) with in a 15(S)-HpETE to 12(S)-HpETE product ratio of ~4-9 to 1.[9] Both products may be rapidly reduced by ubiquitous cellular enzymes with peroxide-reducing activity to form their corresponding hydroxy analogs, 15(S)-HETE (see 15-hydroxyicosatetraenoic acid) and 12(S)-HETE (see 12-Hydroxyeicosatetraenoic acid). 15(S)-HpETE and 15(S)-HETE bind to and activate the Leukotriene B4 receptor 2, activate the Peroxisome proliferator-activated receptor gamma, and at high concentrations cause cells to generate toxic reactive oxygen species; one or more of these effects may be at least in part responsible for their ability to alter the growth of various times of human cancer cell lines, contract various types of blood vessels, and stimulate pathological fibrosis in pulmonary arteries and liver (see 15-Hydroxyicosatetraenoic acid##Activities of parent metabolites and their metabolites###15(S)-HpETE and 15(S)-HETE). 15(S)-HpETE and 15(S)-HETE esterified into the membrane phospholipids of the mitochondria in red blood cell precursors may signal for the intracellular degradation of these mitochondria and thereby the maturation of these precursors to red blood cells in mice. However, this pathway operates along with two other mitochondria-removing pathways and therefore does not appear essential for mouse red blood cell maturation.[2]

15-(S)-HpETE and/or 15(S)-HETE are further metabolized by 15-LOX-1 or other lipoxygenases to various dihydroxy, epoxy-hydroxy, and trihydroxy compounds such as 8(S), 15(S)-dihydroxy-eicosatetraenoic acid (8(S); 15(S)-diHETE); 8(R),15(S)-diHETE; 5(S),15(S)-diHETE; 14(R), 15(S)-diHETE; 5-oxo-15(S)-hydroxy-ETE; certain hepoxilin isomers (e.g. 11S-hydroxy-14S, 15S-epoxy-5Z, 8Z, 12E-eicosatrienoic acid [14,15-HXA3] and 13R-hydroxy-14S, 15S-epoxy-5Z, 8Z, 11Z-eicosatrienoic acid [14,15-HXB3]); various eoxins (e.g. eoxin C4, 14,15-eoxin D4, and eoxin E4); and lipoxins such as LXA4 and LXB4.[2][10][11] 5-oxo-15(S)-hydroxy-ETE is a potent stimulator of human eosinophil and neutrophil chemotaxis and is thereby suggested to contribute to human allergic and non-allergic inflammation responses (see 5-Hydroxyicosatetraenoic acid##Clinical significance###Inflammation and 5-Hydroxyicosatetraenoic acid##Clinical significance###Allergy). The hepoxilin isomers, similar to other hepoxilins viz., HXA3 and HXB3, may also contribute to the regulation of inflammation responses and to stimulating the secretion of insulin (see hepoxilins.[2] The eoxins have been suggested to have pro-inflammatory actions that contribute to in severe asthma, aspirin-induced asthma attacks, and other allergy reactions and to be involved in the lymphoma of Hodgkins disease (see (Eoxins).

15(S)-HETE is oxidized by NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (NAD+) to its keto analog, 15-oxo-ETE, which inhibits the growth of cultured Human umbilical vein endothelial cells and various human cancer cell lines; it is also has activities on THP1 cell line cells suggesting that it might act as an inhibitor of inflammatory and oxidative stress reactions (see15-Hydroxyicosatetraenoic acid##Activities of parent metabolites and their metabolites###15-oxo-ETE)

Human 15-LOX-1 prefers linoleic acid over arachidonic acid as its primary ω-6 polyunsaturated fatty acid (see Omega-6 fatty acid) substrate, oxygenating it at carbon 13 to form 13(S)-hydroperoxy-9Z, 11E-octadecaenoic acid (13-HpODE or 13(S)-HpODE) which may then be reduce to the corresponding hydroxy derivative, 13(S)-HODE or 13-HODE (see 13-Hydroxyoctadecadienoic acid). Non-human 15-LOX1 orthologs such as mouse 12/15-LOX and soybean 15-LOX form, in addition to 13(S)-HODE, metabolize linoleic acid to 9-hydroperoxy-10E, 12Z-octadecaenoic acid (9-HpODE or 9(S)-HpODE), which in mice is rapidly converted to 9(S)-HODE (9-HODE) (see 9-Hydroxyoctadecadienoic acid.[12][13] The sited arachidonic and linoleic acid metabolites have significant bioactivities and potential but unproven clinical relevancies.[11][14][15][16][17] 13(S)-HODE acts through Peroxisome proliferator-activated receptors and the TRPV1 and human GPR132 receptors to stimulate a variety of responses related to monocyte maturation, lipid metabolism, and neuron activation (see 13-Hydroxyoctadecadienoic acid##Activities of 13-HODEs; 9(S)-HODE is a marker for diseases involving oxidative stress and may contribute to this disease as well as to pain perception and atherosclerosis (see 9-Hydroxyoctadecadienoic acid##Biological and clinical relevancy of 9-HODEs).

Human 15-LOX-1 also acts on ω-3 polyunsaturated fatty acids (see Omega-3 fatty acid): it metabolizes α-linolenic acid to 13(S)-hydroperoxy-9Z, 11E, 15Z)-octadecatrienoic acid;[18] eicosapentaenoic acid to 15(S)-hydroperoxy-5Z, 8Z, 11Z, 13E, 17Z-eicosatetraenoic acid (15(S)-HpEPA);[19] and docosahexaenoic acid to 17(S)-hydroperoxy-4Z, 7Z, 10Z, 13Z, 15E, 19Z-docosahexaenoic acid (17-HpDHA) and to neuroprotectin D1 (i.e. 10(R), 17(S)-dihydroxy-4Z, 7Z, 11E, 13E, 15Z, 19Z-docosahexaenoic acid, also designated protectin D1).[7][20][21] 15(S)-HpEPA and 17(S)-HpDHA are reduced to 15(S)-hydroxy-5Z, 8Z, 11Z, 13E, 17Z-eicosatetraenoic acid (15-HEPA or 15(S)-HEPA) and 17(S)-hydroxy-4Z, 7Z, 10Z, 13Z, 15E, 19Z-docosahexaenoic acid (17-HDHA or 17(S)-HDHA), respectively; all of these metabolites possess various and often overlapping bioactivities.[19][22][23][24][25] The 15-(S)-hydroxyl metabolites of α-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and protectin D1 have potent antinflammatory activities.[26] Protectin D1 also has activities in the retina, in Alzheimer's disease, and in the protection of certain viral diseases (see Protectin D1##Functions of PD1. 17(S)-HDHA and its 17(S)-hydoperoxy percrusor are also potent inhibitors of the growth of cultured human prostate cancer cells.[27]

15-LOX-1 also works in conjunction with other oxygenating enzymes to form a wide range of products that inhibit, limit, and resolve inflammatory reactions. 15-LOX-1 acts in series with: a) 5-LOX to metabolize arachidonic acid to lipoxins; b) with 5-LOX to metabolize docosahexaenoic acid to resolvins D1, D2, D3, D4, D5, and D6; and c) aspirin-treated cyclooxygenase-2 or cytochrome P450 enzymes to metabolize eicosapentaenoic acid to resolvin E3.[11][20][28]

Clinical significance

Inflammatory diseases

À huge and growing number of studies in animal models suggest that 15-LOX-1 and its lipoxin, resolvin, and protectin metabolites act to inhibit, limit, and resolve diverse inflammatory diseases including periodontitis, peritonitis, sepsis, and other pathogen-induced inflammatory responses; in eczema, arthritis, asthma, cystic fibrosis, atherosclerosis, and adipose tissue inflammation; in the insulin resistance that occurs in obesity that is associated with diabetes and the metabolic syndrome; and in Alzheimer's disease.[11][20][29][30][31] While these studies have not yet been shown to translate to human diseases, first and second generation synthetic resolvins and lipoxins, which unlike their natural analogs, are relatively resistant to metabolic inactivation, have been made and tested as inflammation inhibitors in animal models.[32] These synthetic analogs may prove to be clinically useful for treating the cited human inflammatory diseases.

By metabolizing the ω-3 polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid, into 17-HpDHA, 17-HDHA, and the resolvins and protectins, 15-LOX-1's metabolic action is thought to be one mechanism by which dietary ω-3 polyunsaturated fatty acids, particularly fish oil, act to ameliorate inflammation, inflammation-related diseases, and certain cancers.[7][20]

Asthma

15-LOX-1 and its 5-oxo-15-hydroxy-ETE and eoxin metabolites have been suggested as potential contributors to, and therefore targets for the future study and treatment of, human allergen-induced asthma, aspirin-induced asthma, and perhaps other allergic diseases.[33][34]

Cancer

In colorectal, breast, and kidney cancers, 15-LOX-1 levels are low or absent compared to the cancers' normal tissue counterparts and/or these levels sharply decline as the cancers progress.[6][20][35] These results, as well as a 15-LOX-1 transgene study on colon cancer in mice[36] suggests but do not prove[37] that 15-LOX-1 is a tumor suppressor.

By metabolizing ω-3 polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid, into lipoxins and resolvins, 15-LOX-1 is thought to be one mechanism by which dietary ω-3 polyunsaturated fatty acids, particularly fish oil, may act to reduce the incidence and/or progression of certain cancers.[20] Indeed, the ability of docosahexaenoic acid to inhibit the growth of cultured human prostate cancer cells is totally dependent upon the expression of 15-LOX-1 by these cells and appears due to this enzyme's production of docosahexaenoic acid metabolites such as 17(S)-HpETE, 17(S)-HETE, and/or and, possibly, an isomer of protectin DX (10S, 17S-dihydroxy-4Z, 7Z, 11E, 13Z, 15E, 19Z-docosahexaenoic acid)[7][38]

See also

References

  1. 1 2 Funk CD, Funk LB, FitzGerald GA, Samuelsson B (May 1992). "Characterization of human 12-lipoxygenase genes". Proceedings of the National Academy of Sciences of the United States of America 89 (9): 3962–6. doi:10.1073/pnas.89.9.3962. PMC 525611. PMID 1570320.
  2. 1 2 3 4 5 6 7 8 9 10 Ivanov I, Kuhn H, Heydeck D (November 2015). "Structural and functional biology of arachidonic acid 15-lipoxygenase-1 (ALOX15)". Gene 573 (1): 1–32. doi:10.1016/j.gene.2015.07.073. PMID 26216303.
  3. ↑ Brash AR, Boeglin WE, Chang MS (June 1997). "Discovery of a second 15S-lipoxygenase in humans". Proceedings of the National Academy of Sciences of the United States of America 94 (12): 6148–52. doi:10.1073/pnas.94.12.6148. PMC 21017. PMID 9177185.
  4. ↑ Claesson HE (September 2009). "On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma". Prostaglandins & Other Lipid Mediators 89 (3-4): 120–5. doi:10.1016/j.prostaglandins.2008.12.003. PMID 19130894.
  5. ↑ Jiang WG, Watkins G, Douglas-Jones A, Mansel RE (April 2006). "Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer". Prostaglandins, Leukotrienes, and Essential Fatty Acids 74 (4): 235–45. doi:10.1016/j.plefa.2006.01.009. PMID 16556493.
  6. 1 2 Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM (December 2005). "The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis". Cancer Research 65 (24): 11486–92. doi:10.1158/0008-5472.can-05-2180. PMC 1564070. PMID 16357157.
  7. 1 2 3 4 Hu Y, Sun H, O'Flaherty JT, Edwards IJ (January 2013). "15-Lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells". Carcinogenesis 34 (1): 176–82. doi:10.1093/carcin/bgs324. PMC 3584949. PMID 23066085.
  8. ↑ Kuhn H, Banthiya S, van Leyen K (April 2015). "Mammalian lipoxygenases and their biological relevance". Biochimica et Biophysica Acta 1851 (4): 308–30. doi:10.1016/j.bbalip.2014.10.002. PMC 4370320. PMID 25316652.
  9. ↑ Bryant RW, Bailey JM, Schewe T, Rapoport SM (June 1982). "Positional specificity of a reticulocyte lipoxygenase. Conversion of arachidonic acid to 15-S-hydroperoxy-eicosatetraenoic acid". The Journal of Biological Chemistry 257 (11): 6050–5. PMID 6804460.
  10. ↑ Claesson HE, Griffiths WJ, Brunnström A, Schain F, Andersson E, Feltenmark S, Johnson HA, Porwit A, Sjöberg J, Björkholm M (August 2008). "Hodgkin Reed-Sternberg cells express 15-lipoxygenase-1 and are putative producers of eoxins in vivo: novel insight into the inflammatory features of classical Hodgkin lymphoma". The FEBS Journal 275 (16): 4222–34. doi:10.1111/j.1742-4658.2008.06570.x. PMID 18647347.
  11. 1 2 3 4 Romano M, Cianci E, Simiele F, Recchiuti A (August 2015). "Lipoxins and aspirin-triggered lipoxins in resolution of inflammation". European Journal of Pharmacology 760: 49–63. doi:10.1016/j.ejphar.2015.03.083. PMID 25895638.
  12. ↑ Rankin SM, Parthasarathy S, Steinberg D (March 1991). "Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages". Journal of Lipid Research 32 (3): 449–56. PMID 1906087.
  13. ↑ "Proof of the enzymatic formation of 9-hydroperoxy-10-trans, 12-cis-octadecadienoic acid from linoleic acid by soya lipoxygenase". Biochim Biophys Acta. 202 (1): 198–9. Feb 1970. doi:10.1016/0005-2760(70)90235-3.
  14. ↑ Moreno JJ (January 2009). "New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development". Biochemical Pharmacology 77 (1): 1–10. doi:10.1016/j.bcp.2008.07.033. PMID 18761324.
  15. ↑ Porro B, Songia P, Squellerio I, Tremoli E, Cavalca V (August 2014). "Analysis, physiological and clinical significance of 12-HETE: a neglected platelet-derived 12-lipoxygenase product". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 964: 26–40. doi:10.1016/j.jchromb.2014.03.015. PMID 24685839.
  16. ↑ Zhu D, Ran Y (May 2012). "Role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in hypoxia-induced pulmonary hypertension". The Journal of Physiological Sciences 62 (3): 163–72. doi:10.1007/s12576-012-0196-9. PMID 22331435.
  17. ↑ Rolin J, Maghazachi AA (April 2014). "Implications of chemokines, chemokine receptors, and inflammatory lipids in atherosclerosis". Journal of Leukocyte Biology 95 (4): 575–85. doi:10.1189/jlb.1113571. PMID 24493826.
  18. ↑ "Mammalian arachidonate 15-lipoxygenases". Prostaglandins Other Lipid Mediat. 68-69: 263–90. Aug 2002. doi:10.1016/s0090-6980(02)00035-7.
  19. 1 2 Vang K, Ziboh VA (May 2005). "15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids". Prostaglandins, Leukotrienes, and Essential Fatty Acids 72 (5): 363–72. doi:10.1016/j.plefa.2005.02.002. PMID 15850718.
  20. 1 2 3 4 5 6 López-Vicario C, Rius B, Alcaraz-Quiles J, García-Alonso V, Lopategi A, Titos E, Clària J (May 2015). "Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases". European Journal of Pharmacology. doi:10.1016/j.ejphar.2015.03.092. PMID 25987424.
  21. ↑ Calandria JM, Marcheselli VL, Mukherjee PK, Uddin J, Winkler JW, Petasis NA, Bazan NG (June 2009). "Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1". The Journal of Biological Chemistry 284 (26): 17877–82. doi:10.1074/jbc.M109.003988. PMC 2719426. PMID 19403949.
  22. ↑ "The significance of polyunsaturated fatty acids in cutaneous biology". Lipids 31: S249–53. Mar 1996. doi:10.1007/bf02637085.
  23. ↑ O'Flaherty JT, Hu Y, Wooten RE, Horita DA, Samuel MP, Thomas MJ, Sun H, Edwards IJ (2012). "15-lipoxygenase metabolites of docosahexaenoic acid inhibit prostate cancer cell proliferation and survival". PloS One 7 (9): e45480. doi:10.1371/journal.pone.0045480. PMC 3447860. PMID 23029040.
  24. ↑ Neuhofer A, Zeyda M, Mascher D, Itariu BK, Murano I, Leitner L, Hochbrugger EE, Fraisl P, Cinti S, Serhan CN, Stulnig TM (June 2013). "Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation". Diabetes 62 (6): 1945–56. doi:10.2337/db12-0828. PMC 3661630. PMID 23349501.
  25. ↑ Ramon S, Baker SF, Sahler JM, Kim N, Feldsott EA, Serhan CN, Martínez-Sobrido L, Topham DJ, Phipps RP (December 2014). "The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?". Journal of Immunology 193 (12): 6031–40. doi:10.4049/jimmunol.1302795. PMC 4258475. PMID 25392529.
  26. ↑ Ziboh VA, Miller CC, Cho Y (January 2000). "Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites". The American Journal of Clinical Nutrition 71 (1 Suppl): 361S–6S. PMID 10617998.
  27. ↑ O'Flaherty JT, Hu Y, Wooten RE, Horita DA, Samuel MP, Thomas MJ, Sun H, Edwards IJ (2012). "15-lipoxygenase metabolites of docosahexaenoic acid inhibit prostate cancer cell proliferation and survival". PloS One 7 (9): e45480. doi:10.1371/journal.pone.0045480. PMC 3447860. PMID 23029040.
  28. ↑ "Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes.". Proc Natl Acad Sci U S A. 81 (17): 5335–9. Sep 1984. doi:10.1073/pnas.81.17.5335.
  29. ↑ Cole BK, Lieb DC, Dobrian AD, Nadler JL (Jul 2013). "12- and 15-lipoxygenases in adipose tissue inflammation". Prostaglandins & Other Lipid Mediators. 104-105: 84–92. doi:10.1016/j.prostaglandins.2012.07.004. PMC 3526691. PMID 22951339.
  30. ↑ Russell CD, Schwarze J (February 2014). "The role of pro-resolution lipid mediators in infectious disease". Immunology 141 (2): 166–73. doi:10.1111/imm.12206. PMC 3904237. PMID 24400794.
  31. ↑ Serhan CN, Chiang N, Dalli J (May 2015). "The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution". Seminars in Immunology 27 (3): 200–15. doi:10.1016/j.smim.2015.03.004. PMID 25857211.
  32. ↑ Orr SK, Colas RA, Dalli J, Chiang N, Serhan CN (May 2015). "Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent". American Journal of Physiology. Lung Cellular and Molecular Physiology 308 (9): L904–11. doi:10.1152/ajplung.00370.2014. PMC 4421783. PMID 25770181.
  33. ↑ James A, Daham K, Backman L, Brunnström A, Tingvall T, Kumlin M, Edenius C, Dahlén SE, Dahlén B, Claesson HE (2013). "The influence of aspirin on release of eoxin C4, leukotriene C4 and 15-HETE, in eosinophilic granulocytes isolated from patients with asthma". International Archives of Allergy and Immunology 162 (2): 135–42. doi:10.1159/000351422. PMID 23921438.
  34. ↑ Neighbour H (2014). "Mechanisms of aspirin-intolerant asthma: identifying inflammatory pathways in the pathogenesis of asthma". International Archives of Allergy and Immunology 163 (1): 1–2. doi:10.1159/000355949. PMID 24247362.
  35. ↑ Gohara A, Eltaki N, Sabry D, Murtagh D, Jankun J, Selman SH, Skrzypczak-Jankun E (October 2012). "Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer". Oncology Reports 28 (4): 1275–82. doi:10.3892/or.2012.1924. PMID 22825379.
  36. ↑ Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi I (May 2012). "Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice". Journal of the National Cancer Institute 104 (9): 709–16. doi:10.1093/jnci/djs187. PMC 3341308. PMID 22472308.
  37. ↑ Umar A (May 2012). "Is 15-LOX-1 a tumor suppressor?". Journal of the National Cancer Institute 104 (9): 645–7. doi:10.1093/jnci/djs192. PMID 22472307.
  38. ↑ O'Flaherty JT, Hu Y, Wooten RE, Horita DA, Samuel MP, Thomas MJ, Sun H, Edwards IJ (2012). "15-lipoxygenase metabolites of docosahexaenoic acid inhibit prostate cancer cell proliferation and survival". PloS One 7 (9): e45480. doi:10.1371/journal.pone.0045480. PMC 3447860. PMID 23029040.

Further reading

  • Kelavkar U, Glasgow W, Eling TE (June 2002). "The effect of 15-lipoxygenase-1 expression on cancer cells". Current Urology Reports 3 (3): 207–14. doi:10.1007/s11934-002-0066-8. PMID 12084190. 
  • Sigal E, Dicharry S, Highland E, Finkbeiner WE (April 1992). "Cloning of human airway 15-lipoxygenase: identity to the reticulocyte enzyme and expression in epithelium". The American Journal of Physiology 262 (4 Pt 1): L392–8. PMID 1566855. 
  • Izumi T, Rådmark O, Jörnvall H, Samuelsson B (December 1991). "Purification of two forms of arachidonate 15-lipoxygenase from human leukocytes". European Journal of Biochemistry / FEBS 202 (3): 1231–8. doi:10.1111/j.1432-1033.1991.tb16495.x. PMID 1662607. 
  • Conrad DJ, Kuhn H, Mulkins M, Highland E, Sigal E (January 1992). "Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase". Proceedings of the National Academy of Sciences of the United States of America 89 (1): 217–21. doi:10.1073/pnas.89.1.217. PMC 48207. PMID 1729692. 
  • Lei ZM, Rao CV (February 1992). "The expression of 15-lipoxygenase gene and the presence of functional enzyme in cytoplasm and nuclei of pregnancy human myometria". Endocrinology 130 (2): 861–70. doi:10.1210/en.130.2.861. PMID 1733732. 
  • Izumi T, Rådmark O, Samuelsson B (1991). "Purification of 15-lipoxygenase from human leukocytes, evidence for the presence of isozymes". Advances in Prostaglandin, Thromboxane, and Leukotriene Research 21A: 101–4. PMID 1825526. 
  • Sloane DL, Leung R, Craik CS, Sigal E (November 1991). "A primary determinant for lipoxygenase positional specificity". Nature 354 (6349): 149–52. doi:10.1038/354149a0. PMID 1944593. 
  • Nadel JA, Conrad DJ, Ueki IF, Schuster A, Sigal E (April 1991). "Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells". The Journal of Clinical Investigation 87 (4): 1139–45. doi:10.1172/JCI115110. PMC 295116. PMID 2010530. 
  • Kroschwald P, Kroschwald A, Kühn H, Ludwig P, Thiele BJ, Höhne M, Schewe T, Rapoport SM (April 1989). "Occurrence of the erythroid cell specific arachidonate 15-lipoxygenase in human reticulocytes". Biochemical and Biophysical Research Communications 160 (2): 954–60. doi:10.1016/0006-291X(89)92528-X. PMID 2719708. 
  • Sigal E, Nadel JA (December 1988). "Arachidonic acid 15-lipoxygenase and airway epithelium. Biologic effects and enzyme purification". The American Review of Respiratory Disease 138 (6 Pt 2): S35–40. doi:10.1164/ajrccm/138.6_pt_2.s35. PMID 3202520. 
  • Sigal E, Craik CS, Highland E, Grunberger D, Costello LL, Dixon RA, Nadel JA (December 1988). "Molecular cloning and primary structure of human 15-lipoxygenase". Biochemical and Biophysical Research Communications 157 (2): 457–64. doi:10.1016/S0006-291X(88)80271-7. PMID 3202857. 
  • Sigal E, Grunberger D, Craik CS, Caughey GH, Nadel JA (April 1988). "Arachidonate 15-lipoxygenase (omega-6 lipoxygenase) from human leukocytes. Purification and structural homology to other mammalian lipoxygenases". The Journal of Biological Chemistry 263 (11): 5328–32. PMID 3356688. 
  • Nassar GM, Morrow JD, Roberts LJ, Lakkis FG, Badr KF (November 1994). "Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes". The Journal of Biological Chemistry 269 (44): 27631–4. PMID 7961680. 
  • Kritzik MR, Ziober AF, Dicharry S, Conrad DJ, Sigal E (June 1997). "Characterization and sequence of an additional 15-lipoxygenase transcript and of the human gene". Biochimica et Biophysica Acta 1352 (3): 267–81. doi:10.1016/s0167-4781(97)00005-5. PMID 9224951. 
  • Brinckmann R, Schnurr K, Heydeck D, Rosenbach T, Kolde G, Kühn H (January 1998). "Membrane translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the oxygenase activity of the enzyme". Blood 91 (1): 64–74. PMID 9414270. 
  • Kelavkar U, Wang S, Montero A, Murtagh J, Shah K, Badr K (July 1998). "Human 15-lipoxygenase gene promoter: analysis and identification of DNA binding sites for IL-13-induced regulatory factors in monocytes". Molecular Biology Reports 25 (3): 173–82. doi:10.1023/A:1006813009006. PMID 9700053. 
  • Roy B, Cathcart MK (November 1998). "Induction of 15-lipoxygenase expression by IL-13 requires tyrosine phosphorylation of Jak2 and Tyk2 in human monocytes". The Journal of Biological Chemistry 273 (48): 32023–9. doi:10.1074/jbc.273.48.32023. PMID 9822675. 
  • Kratky D, Lass A, Abuja PM, Esterbauer H, Kühn H (January 1999). "A sensitive chemiluminescence method to measure the lipoxygenase catalyzed oxygenation of complex substrates". Biochimica et Biophysica Acta 1437 (1): 13–22. doi:10.1016/s0005-2760(98)00176-3. PMID 9931410. 
  • Kelavkar UP, Badr KF (April 1999). "Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene". Proceedings of the National Academy of Sciences of the United States of America 96 (8): 4378–83. doi:10.1073/pnas.96.8.4378. PMC 16340. PMID 10200270. 
This article is issued from Wikipedia - version of the Friday, May 06, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.